Global Darbepoetin Alfa Market Growth 2025-2031

Global Darbepoetin Alfa Market Growth 2025-2031

The global Darbepoetin Alfa market size is predicted to grow from US$ 4534 million in 2025 to US$ 3799 million in 2031; it is expected to grow at a CAGR of -2.9% from 2025 to 2031.

Darbepoetin alfa (INN) is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic renal failure and cancer chemotherapy.

The classification of Darbepoetin Alfa includes Epogen, Procrit, Aranesp and others, and the proportion of Epogen in 2017 is about 45%.

Darbepoetin Alfa is widely used for Patients with Chronic Kidney Disease, Patients with Cancer others. The most proportion of Darbepoetin Alfa is used for the Patients with Chronic Kidney Disease, and the proportion in 2017 is 62%.

North America is the largest consumption place, with a consumption market share nearly 47% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 41%.

Market competition is not intense. Amgen, Johnson & Johnson, Kyowa Hakko Kirin, Novartis and 3SBio etc. are the leaders of the industry, with about 87% market shares.

LP Information, Inc. (LPI) ' newest research report, the “Darbepoetin Alfa Industry Forecast” looks at past sales and reviews total world Darbepoetin Alfa sales in 2024, providing a comprehensive analysis by region and market sector of projected Darbepoetin Alfa sales for 2025 through 2031. With Darbepoetin Alfa sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Darbepoetin Alfa industry.

This Insight Report provides a comprehensive analysis of the global Darbepoetin Alfa landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Darbepoetin Alfa portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Darbepoetin Alfa market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Darbepoetin Alfa and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Darbepoetin Alfa.

This report presents a comprehensive overview, market shares, and growth opportunities of Darbepoetin Alfa market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Epogen
Procrit
Aranesp
Others

Segmentation by Application:
Patients with Chronic Kidney Disease
Patients with Cancer
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Amgen
Johnson & Johnson
Kyowa Hakko Kirin
Novartis
3SBio

Key Questions Addressed in this Report

What is the 10-year outlook for the global Darbepoetin Alfa market?

What factors are driving Darbepoetin Alfa market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Darbepoetin Alfa market opportunities vary by end market size?

How does Darbepoetin Alfa break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.